Literature DB >> 1918070

Oligomeric binding of T3 receptor is required for maximal T3 response.

G R Williams1, J W Harney, B M Forman, H H Samuels, G A Brent.   

Abstract

Receptors in the thyroid-steroid hormone superfamily bind preferentially as dimers to palindromic response elements containing two hexameric half-sites. The 23-base pair rat growth hormone (rGH) T3 response element (T3RE), however, contains three hexameric binding domains, all of which are required for maximal T3 response. We examined the binding of purified T3 receptor alpha (T3R alpha), overexpressed in Escherichia coli, to wild-type and up and down mutations of the rGH T3RE to evaluate whether transcriptional potency correlates with changes in T3R binding. T3R binds to the rGH T3RE as a monomer, dimer, or higher order oligomer. Cooperative T3R dimer binding was demonstrated to two hexameric domains of the rGH T3RE arranged as either direct or inverted repeats. Decreased binding was seen with point mutations in each domain as well as with mutations which altered hexamer orientation and spacing within the site. These results demonstrate that all three hexamers of the rGH T3RE are involved in binding T3R. Occupancy of all three hexamers by T3R in the gel shift assay was observed with functional up mutations of the T3RE, increasing receptor concentration or addition of nuclear extract. The transcriptional response potencies of T3RE up or down mutants in a transient transfection assay correlated closely with T3R binding. These results confirm our earlier hypothesis that all three hexamers of the rGH T3RE bind T3R in a novel binding arrangement and provide a model for the interaction of T3R and other nuclear proteins with the DNA sequences of thyroid hormone-regulated genes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918070

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Structure of a thyroid hormone receptor DNA-binding domain homodimer bound to an inverted palindrome DNA response element.

Authors:  Yi Chen; Matthew A Young
Journal:  Mol Endocrinol       Date:  2010-07-07

2.  Molecular basis for dimer formation of TRbeta variant D355R.

Authors:  Natalia Jouravel; Elena Sablin; Marie Togashi; John D Baxter; Paul Webb; Robert J Fletterick
Journal:  Proteins       Date:  2009-04

Review 3.  Human nuclear receptor heterodimers: opportunities for detecting targets of transcriptional regulation using yeast.

Authors:  T R Butt; P G Walfish
Journal:  Gene Expr       Date:  1996

4.  Identification of a functional thyroid hormone response element in the upstream flanking region of the human Na,K-ATPase beta 1 gene.

Authors:  J Feng; J Orlowski; J B Lingrel
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

5.  Cloning and characterization of two novel thyroid hormone receptor beta isoforms.

Authors:  G R Williams
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

6.  DNA bending by thyroid hormone receptor: influence of half-site spacing and RXR.

Authors:  K Shulemovich; D D Dimaculangan; D Katz; M A Lazar
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

Review 7.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

8.  The NF-kappa B and Sp1 motifs of the human immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response elements.

Authors:  V Desai-Yajnik; H H Samuels
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

9.  Coactivator recruitment is enhanced by thyroid hormone receptor trimers.

Authors:  Brenda J Mengeling; Sangho Lee; Martin L Privalsky
Journal:  Mol Cell Endocrinol       Date:  2007-10-06       Impact factor: 4.102

10.  Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta 1 receptors.

Authors:  R Wong; X G Zhu; M A Pineda; S Y Cheng; B D Weintraub
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.